Alto Neuroscience stockholders elected one director, ratified Deloitte as auditors, rejected 2024 Equity Incentive Plan amendment, but approved Amended and Restated 2024 Employee Stock Purchase Plan at the 2026 Annual Meeting.
Key takeaways
Stockholders elected Raymond Sanchez, M.D. as Class II director (23.1M for, 31K withheld) but withheld votes from Gwill York (12.4M for, 10.8M withheld).
Ratified Deloitte & Touche LLP as independent auditors for FY 2026 with 26.7M for votes.
Rejected amendment to 2024 Equity Incentive Plan (10.8M for vs 12.2M against).
Approved A&R 2024 ESPP amendment (11.9M for vs 11.1M against), adopted by Board on March 16, 2026.
83.77% of 31.9M outstanding shares present at May 12, 2026 Annual Meeting.